T cell subsets in chronic hepatitis B and the effect of prednisolone withdrawal and interferon alpha-2b

Objectives The evaluations of the pathogenetic roles of cell mediated immunity and of the preventive effect for disease progression with interferon(IFN) treatment in patients with chronic active hepatitis-B(CAH-B) are the objectives of this study. Methods Thirty-two patients with CAH-B were treated with interferon α-2b(IFN α-2b) with prednisolone withdrawal and 30 control patients were treated with conventional hepatotonics for 6 months. Peripheral total T cell fractions and T cell subsets of the patients with CAH-B, treated with IFNα-2b with prednisolone withdrawal, were examined 1 month before administration of prednisolone, and compared with 12 normal controls for assessing the potential role of cellular immunity in the development of CAH-B. To estimate the effectiveness of IFN therapy for the patients with CAH-B, levels of various liver function tests, HBsAg, anti-HBs, HBeAg, anti-HBe, HBV DNA, anti-HCV and others were assessed for the treatment group and compared with control patients at pre- and post-treatment period each. Results The value of CD4 was significantly lower in patients with CAH-B than normal controls(36.3±7.7% vs 42.1±5.7%, p<0.05) and the value of CD8 was significantly higher in patients with CAH-B than normal controls(30.6±10.3% vs 24.3±5.2%, p<0.05) before prednisolone administration. The patients in responder group (n=26) had significantly lower CD4 cells compared with normal controls, but non-responders (n=6) did not have. The levels of liver function test (LFT) in the patients with IFN α-2b treatment with, prednisolone withdrawal were not different from the control patient group at pretreatment, but significantly lower than control patient group’s after treatment, regardless of response to IFN α-2b treatment with prednisolone withdrawal. Conclusions The cellular immunity of the host may have a potential role in the pathogenesis of chronicity of hepatitis B infection. IFN α-2b treatment with prednisolone withdrawal may be regarded as one of the effective treatment modalities for the inhibition of disease progression in patients with CAH-B.

[1]  P. Marcellin,et al.  Treatment of chronic viral hepatitis. , 1994, Bailliere's clinical gastroenterology.

[2]  F. Dianzani,et al.  Decreased interferon response by lymphocytes from children with chronic hepatitis. , 1975, Journal of interferon research.

[3]  G. Alexander,et al.  Detection of HBV-DNA using a digoxigenin-labelled probe. A rapid technique without loss of sensitivity. , 1991, Journal of hepatology.

[4]  M. Peters,et al.  Prednisone withdrawal followed by recombinant alpha interferon in the treatment of chronic type B hepatitis. A randomized, controlled trial. , 1988, Annals of internal medicine.

[5]  S. Sherlock.  Treatment of chronic viral hepatitis. , 1988, Journal of hepatology.

[6]  A. Lok,et al.  Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection. , 1987, Gastroenterology.

[7]  R. Müller.  [Antiviral therapy in chronic hepatitis B]. , 1987, Medizinische Klinik.

[8]  J. Hoofnagle,et al.  Effects of immunosuppressive therapy with prednisolone on B and T lymphocyte function in patients with chronic type B hepatitis , 1986, Hepatology.

[9]  M. Rugge,et al.  Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti‐HBe in chronic hepatitis type B , 1986, Hepatology.

[10]  J. Hoofnagle,et al.  Pilot study of recombinant human α-interferon for chronic type B hepatitis , 1986 .

[11]  J. Hoofnagle,et al.  Pilot study of recombinant human alpha-interferon for chronic type B hepatitis. , 1986, Gastroenterology.

[12]  H. Thomas,et al.  A randomized study of the effects of adenine arabinoside 5′‐monophosphate (short or long courses) and lymphoblastoid interferon on hepatitis B virus replication , 1985, Hepatology.

[13]  S. Schalm,et al.  ACYCLOVIR ENHANCES THE ANTIVIRAL EFFECT OF INTERFERON IN CHRONIC HEPATITIS B , 1985, The Lancet.

[14]  O. Yokosuka,et al.  Recombinant leukocyte a interferon treatment in patients with chronic hepatitis B virus infection. Pharmacokinetics, tolerance, and biologic effects. , 1985, Gastroenterology.

[15]  V. Barnaba,et al.  Relationship between T cell subsets and suppressor cell activity in chronic hepatitis B virus (HBV) infection. , 1983, Clinical and experimental immunology.

[16]  J. Hoofnagle.  Chronic type B hepatitis. , 1983, Gastroenterology.

[17]  Kenichi Kobayashi,et al.  Interferon production by peripheral lymphocytes in HBsAg‐positive liver diseases , 1982, Hepatology.

[18]  S. Poppema,et al.  CELLULAR AND HUMORAL IMMUNE-REACTIONS IN CHRONIC ACTIVE LIVER-DISEASE .1. LYMPHOCYTE SUBSETS IN LIVER BIOPSIES OF PATIENTS WITH UNTREATED IDIOPATHIC AUTOIMMUNE HEPATITIS, CHRONIC ACTIVE HEPATITIS-B AND PRIMARY BILIARY-CIRRHOSIS , 1982 .

[19]  S. Sherlock,et al.  Successful treatment of HBs and HBeAg positive chronic liver disease: prolonged inhibition of viral replication by highly soluble adenine arabinoside 5'-monophosphate (ARA-AMP). , 1982, Gut.

[20]  G. Mieli-Vergani,et al.  Lymphocyte cytotoxicity to autologous hepatocytes in chronic hepatitis B virus infection , 1982 .

[21]  S. Sherlock,et al.  Adenine arabinoside therapy in HBsAg-positive chronic liver disease: a controlled study. , 1981, Gastroenterology.

[22]  M. Colombo,et al.  T and B lymphocytes in patients with chronic active hepatitis (CAH). , 1977, Clinical and experimental immunology.

[23]  S. Sherlock,et al.  Peripheral blood lymphocyte populations in chronic liver disease. , 1976, Clinical and experimental immunology.

[24]  S. Sherlock,et al.  Cellular immunity and hepatitis-associated, Australia antigen liver disease. , 1972, Lancet.

[25]  A. Bøyum,et al.  Separation of leukocytes from blood and bone marrow. Introduction. , 1968 .